{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=11", "query": { "intervention": "serum sample", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 8367, "total_pages": 837, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T07:44:20.803Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01382940", "title": "A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 351, "start_date": "2011-07-26", "completion_date": "2013-01-06", "has_results": true, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382940" }, { "nct_id": "NCT03763643", "title": "PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Focal Segmental Glomerulosclerosis" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Plasmapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 21, "start_date": "2019-07-01", "completion_date": "2025-02-07", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 12, "location_summary": "Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Davis", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Aurora", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03763643" }, { "nct_id": "NCT03062878", "title": "The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Lymphoma", "Chemotherapy Effect" ], "interventions": [ { "name": "Arterial blood pressure", "type": "OTHER" }, { "name": "Vascular Ultrasound", "type": "OTHER" }, { "name": "Venous blood sample", "type": "OTHER" }, { "name": "Skin microcirculatory blood flow", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Carl Ade, M.S., Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 60, "start_date": "2017-02-01", "completion_date": "2018-08-01", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 1, "location_summary": "Manhattan, Kansas", "locations": [ { "city": "Manhattan", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03062878" }, { "nct_id": "NCT00054574", "title": "Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": null, "start_date": "2002-11", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 2, "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054574" }, { "nct_id": "NCT00808210", "title": "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-03-05", "completion_date": "2012-11-14", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808210" }, { "nct_id": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Ovarian Cancer", "Gastric Cancer", "Palpable Subcutaneous Malignant Lesions", "Renal Cell Carcinoma", "Melanoma", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Imiquimod Cream", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2019-04-26", "completion_date": "2026-07-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872947" }, { "nct_id": "NCT02693535", "title": "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Multiple Myeloma", "Advanced Solid Tumors" ], "interventions": [ { "name": "Sunitinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Olaparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Abemaciclib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)", "type": "DRUG" }, { "name": "Futibatinib", "type": "DRUG" }, { "name": "Dabrafenib plus Trametinib", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki (TDxD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "American Society of Clinical Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 4200, "start_date": "2016-03-14", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 174, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02693535" }, { "nct_id": "NCT06124391", "title": "Novel Subtypes of Polycystic Ovary Syndrome", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycystic Ovary Syndrome" ], "interventions": [ { "name": "Long-term follow-up", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Shandong University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 50000, "start_date": "2021-01-01", "completion_date": "2025-12-30", "has_results": false, "last_update_posted_date": "2023-11-30", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06124391" }, { "nct_id": "NCT04074785", "title": "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "GBM", "Glioblastoma", "Brain Tumor", "Brain Tumor, Recurrent" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2019-12-13", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2025-08-17", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04074785" }, { "nct_id": "NCT01921218", "title": "Belatacept Therapy for the Failing Renal Allograft", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Failing Renal Allograft" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Calcineurin inhibitor therapy", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew B Adams", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 13, "start_date": "2013-08", "completion_date": "2019-12-12", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-10-16T07:44:20.803Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921218" } ] }